Biogen (BIIB) Misses Q4 EPS by 23c, Offers Guidance
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $216.73 -0.19%
Revenue Growth %: +4.3%
Financial Fact:
Selling, general and administrative: 462.7M
Today's EPS Names:
OCCI, VIVO, PMCB, More
Revenue Growth %: +4.3%
Financial Fact:
Selling, general and administrative: 462.7M
Today's EPS Names:
OCCI, VIVO, PMCB, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q4 EPS of $2.95, $0.23 worse than the analyst estimate of $3.18. Revenue for the quarter came in at $2.4 billion versus the consensus estimate of $2.47 billion.
GUIDANCE:
Biogen sees FY2024 EPS of $15.00-$16.00, versus the consensus of $15.64.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercore cuts HPE rating amid 'tougher setup'
- FDA approves Biofrontera's Ameluz for superficial basal cell carcinoma
- Zumiez, Inc. (ZUMZ) Misses Q2 EPS by 6c, Misses on Revenue; Offers Q3 Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
